Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.), Orlando, FL
Is Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location.
Does Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 4 licenses for this name and city, as of Nov 15, 2026: PH33404 for JUBILANT DRAXIMAGE INC. (dba Jubilant Radiopharma), ORLANDO, status Clear, PH33419 for JUBILANT DRAXIMAGE INC (dba Jubilant Radiopharma), ORLANDO, status Clear, PH31096 for JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), ORLANDO, status Closed and PH31097 for JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), ORLANDO, status Closed.
Has Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Aug 13, 2024) and 1 FMD-145 letter (Aug 14, 2024) for Jubilant Radiopharma (Jubilant Draximage Radiopharmacies Inc.). State board actions: no Florida Board of Pharmacy action on licenses PH33404, PH33419, PH31096 and PH31097 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Jubilant Draximage Radiopharmacies Inc.; Jubilant Radiopharma
- Location
- Orlando, FL
- Type as FDA labels it
- Not stated
- FDA’s note
- Nuclear Pharmacy
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Aug 14, 2024
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 6 observations
- State board records
- License found: PH33404, Clear; PH33419, Clear; PH31096, Closed; PH31097, Closed
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Jubilant Draximage Radiopharmacies Inc., (dba Jubilant Radiopharma), with 3 dated actions.
| Document | |||
|---|---|---|---|
| Aug 14, 2024 | FMD-145 letter | FMD-145 Letter Issued 08/14/2024 | Not linked by FDA |
| Aug 13, 2024 | State referral letter | State Referral Letter Issued 08/13/2024 | FDA copy (archived) |
| Mar 13, 2024 | Form 483 | 483 Issued 03/13/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Jubilant DraxImage Radiopharmacies Inc., Orlando, FL (FEI number 3009339218), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 13, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3009339218 | 1232771 |
Form 483s FDA has published for this site
- Mar 13, 2024: Form 483 to Jubilant DraxImage Radiopharmacies Inc., published Jun 13, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 5, 2024 to Mar 13, 2024: 6 observations
- Firm on the cover
- Jubilant Draximage Radiopharmacies Inc. dba Jubilant Radiopharma, 4205 Vineland Rd Ste L13, Orlando, FL 32811-6601
- Establishment type on the cover
- Nuclear Pharmacy
- FDA district office on the cover
- 555 Winderley Pl ace, Suite 200 Maitland, FL 32751
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel were observed performing aseptic processing outside of an ISO 5 area.
Specifically on 03/06/24, during the production of Gozetotide (illucix) Cold Kit Lot# K-20240306-069 your firm's Pharmacy Manager was observed performing the following aseptic connections in the ISO-7 aseptic processing area: connecting the <Redacted B4> sterile <Redacted B4>to the Gallium Generator and connecting the Sterile <Redacted B4> to the Gallium _Generator. The following prescriptions were drawn from tlie cold kit and dispensed: RX <Redacted B4> 1394mCi and RX <Redacted B4> (25.49mCi).
Observation 2
Personnel were observed conducting aseptic manipulations where the movement of 11first air" in the ISO 5 area is blocked or dismpted.
Specifically, on 03/06/24, during the production of Gozetotide (Illucix) Cold Kit Lot# K-20240306-069 your firm's Pharmacy Manager was observed blocking first pass air in the IS0-5 <Redacted B4> flow hood. The following prescriptions were drawn from the cold kit and dispensed: RX <Redacted B4> (13.94 mCi) and RX <Redacted B4> (25.49 mCi).
Observation 3
Use of non-sterile disinfecting agents and cleaning pads in the ISO 5 area.
Specifically, your firm utilizes the following non-sterile cleaning agents <Redacted B4> <Redacted B4> and non-sterile <Redacted B4> within your <Redacted B4> ISO 5 <Redacted B4> flow hoods and <Redacted B4> ISO 5 BSCs.
Observation 4
Smoke studies were inadequately performed under dynamic conditions.
Specifically, on 03/16/24, inadequate smoke studies were observed within your firm's ISO 5 <Redacted B4> flow hood (video-SN:155019, 3:1 5). Turbulent and non-unidirectional airflow was observed during the operations. Ancillary supplies such as syringe containers and a labeling printer were observed blocking the grates and return vent within the hood allowing for air to recirculate.
Observation 5
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, during the current FDA inspection, your firm determined that your media fill is not reflective of Gozetotide (Illucix) which is the most challenging drug product to produce because of the number of manipulations and poses the highest lisk to product sterility due to the transfer from the ISO <Redacted B4> flow hood to the Gallium Generator (requires aseptic connections) that is housed within the ISO 7 aseptic processmg area.
Observation 6
Inadequate routine environmental monitoring in the ISO 5 area and classified areas.
Specifically your firm was unable to determine that viable surface sampling of the ISO-5 environment (e.g., ISO-5 LAFHs and BSCs) occurs prior to cleaning operations.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH33404 | Pharmacy | JUBILANT DRAXIMAGE INC. (dba Jubilant Radiopharma) | ORLANDO | Clear |
| PH33419 | Pharmacy | JUBILANT DRAXIMAGE INC (dba Jubilant Radiopharma) | ORLANDO | Clear |
| PH31096 | Pharmacy | JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma) | ORLANDO | Closed |
| PH31097 | Pharmacy | JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma) | ORLANDO | Closed |
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License PH31077, Jubilant Draximage Radiopharmacies, Inc. (dba Triad Isotopes), PANAMA CITY, status Closed: same name and state, different city.
- License PH31072, JUBILANT DRAXIMAGE RADIOPHARMACIES, INC, PANAMA CITY, status Closed: same name and state, different city.
- License PH33412, JUBILANT DRAXIMAGE INC. (dba Jubilant Radiopharma), WEST MELBOURNE, status Clear: same name and state, different city.
- License PH33415, JUBILANT DRAXIMAGE INC (dba Jubilant Radiopharma), WEST MELBOURNE, status Clear: same name and state, different city.
- License PH31070, JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), WEST MELBOURNE, status Closed: same name and state, different city.
- License PH31076, Jubilant Draximage Radiopharmacies, Inc. (dba Jubilant Radiopharma), WEST MELBOURNE, status Closed: same name and state, different city.
- License PH30985, JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. (dba Jubilant Radiopharma), JACKSONVILLE, status Closed: same name and state, different city.
- License PH30986, Jubilant Draximage Radiopharmacies, Inc. (dba Jubilant Radiopharma), JACKSONVILLE, status Closed: same name and state, different city.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.